Loading...
OTCMGBLP
Market cap4mUSD
Dec 02, Last price  
0.15USD
Name

Global Pharmatech Inc

Chart & Performance

D1W1MN
OTCM:GBLP chart
P/E
P/S
65.24
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
86.20%
Rev. gr., 5y
-53.60%
Revenues
66k
+13.30%
1,555,6703,085,1752,375,5112,819,090058,58566,375
Net income
-138k
L+559.39%
310,085200,695-1,234,391-2,445,204-113,314-21,004-138,499
CFO
-199k
L
1,168,982-1,860,329261,772-383,938-62,638391,443-199,268

Profile

Global Pharmatech, Inc. engages in the research, production, and development of herbal medicine, bio-medicine, chemical medicine, traditional chinese medicine, and dietary supplements primarily in China. The company's principal product line consists of XS CAPSULE (XIN-SHU) for the treatment of angina and other coronary disease; JUTAI SOFT CAPSULE, a dietary supplement; QINGXUAN ANTI-HYPERTENSION TABLET, an over-the-counter drug product indicated for the treatment of hypertension and high serum cholesterol level; and YANREQING TABLET for the treatment of inflammation. It also manufactures and sells other proprietary drugs, generics, and dietary supplements used to treat symptoms ranging from headaches, coughing, and dry mouth to infections, and numbness of limbs. The company markets its products through distributors, such as wholesale companies and chain store representatives, as well as through its sales force. Global Pharmatech, Inc. was founded in 2001 and is based in Changchun, China.
IPO date
May 12, 2006
Employees
217
Domiciled in
CN
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFY
2023‑122022‑122021‑12
Income
Revenues
66
13.30%
59
 
Cost of revenue
23
29
Unusual Expense (Income)
NOPBT
44
29
NOPBT Margin
66.02%
50.18%
Operating Taxes
(237)
Tax Rate
NOPAT
44
29
237
Net income
(138)
559.39%
(21)
-81.46%
(113)
 
Dividends
Dividend yield
Proceeds from repurchase of equity
119
340
64
BB yield
Debt
Debt current
50
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
(26)
12
Cash flow
Cash from operating activities
(199)
391
(63)
CAPEX
199
(229)
Cash from investing activities
23
(229)
Cash from financing activities
165
(131)
64
FCF
96
234
Balance
Cash
21
33
Long term investments
5
5
Excess cash
23
35
Stockholders' equity
(11,923)
(11,927)
(11,455)
Invested Capital
11,722
11,780
11,406
ROIC
0.37%
0.25%
2.07%
ROCE
EV
Common stock shares outstanding
395,212
282,852
276,352
Price
Market cap
EV
EBITDA
44
29
EV/EBITDA
Interest
35
Interest/NOPBT